Onconetix (NASDAQ:ONCO) Stock Price Down 22.1% – What’s Next?

Shares of Onconetix, Inc. (NASDAQ:ONCO) fell 22.1% on Friday . The stock traded as low as $1.27 and last traded at $1.27. 53,879 shares were traded during trading, a decline of 83% from the average session volume of 317,751 shares. The stock had previously closed at $1.63.

Onconetix Stock Performance

The firm has a 50 day moving average of $4.12 and a two-hundred day moving average of $5.42.

Onconetix (NASDAQ:ONCO) last posted its earnings results on Thursday, August 29th. The company reported ($9.20) earnings per share for the quarter. The company had revenue of $0.71 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Onconetix, Inc. (NASDAQ:ONCO) by 83.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 562,691 shares of the company’s stock after buying an additional 256,612 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned 76.04% of Onconetix worth $2,926,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 23.89% of the company’s stock.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.